{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:14:09Z","timestamp":1788560049882,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"DOI":"10.1007\/s00467-026-07518-w","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:30:12Z","timestamp":1788557412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystinosis-associated metabolic bone disease: pathogenesis and outcome"],"prefix":"10.1007","author":[{"given":"Anne","family":"Sch\u00f6n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Szaroszyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"7518_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/jimd.12134","volume":"42","author":"K Hohenfellner","year":"2019","unstructured":"Hohenfellner K, Rauch F, Ariceta G et al (2019) Management of bone disease in cystinosis: statement from an international conference. J Inherit Metab Dis 42:1019\u20131029. https:\/\/doi.org\/10.1002\/jimd.12134","journal-title":"J Inherit Metab Dis"},{"key":"7518_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-026-01089-7","author":"K Hohenfellner","year":"2026","unstructured":"Hohenfellner K, W\u00fchl E, Haffner D et al (2026) Clinical practice recommendations for the diagnosis and management of nephropathic cystinosis. Nat Rev Nephrol. https:\/\/doi.org\/10.1038\/s41581-026-01089-7","journal-title":"Nat Rev Nephrol"},{"key":"7518_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/MOP.0000000000000462","volume":"29","author":"KR Veys","year":"2017","unstructured":"Veys KR, Elmonem MA, Arcolino FO et al (2017) Nephropathic cystinosis: an update. Curr Opin Pediatr 29:168\u2013178. https:\/\/doi.org\/10.1097\/MOP.0000000000000462","journal-title":"Curr Opin Pediatr"},{"key":"7518_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00467-012-2242-5","volume":"28","author":"G Nesterova","year":"2013","unstructured":"Nesterova G, Gahl WA (2013) Cystinosis: the evolution of a treatable disease. Pediatr Nephrol 28:51\u201359. https:\/\/doi.org\/10.1007\/s00467-012-2242-5","journal-title":"Pediatr Nephrol"},{"key":"7518_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00467-025-06790-6","volume":"41","author":"HE Chang","year":"2026","unstructured":"Chang HE, Hossain MS, Song C et al (2026) Long-term outcomes in nephropathic cystinosis: a review. Pediatr Nephrol 41:277\u2013296. https:\/\/doi.org\/10.1007\/s00467-025-06790-6","journal-title":"Pediatr Nephrol"},{"key":"7518_CR6","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.kint.2021.06.019","volume":"100","author":"F Emma","year":"2021","unstructured":"Emma F, Hoff WV, Hohenfellner K et al (2021) An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis. Kidney Int 100:1112\u20131123. https:\/\/doi.org\/10.1016\/j.kint.2021.06.019","journal-title":"Kidney Int"},{"key":"7518_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ymgme.2022.06.009","volume":"136","author":"K Hohenfellner","year":"2022","unstructured":"Hohenfellner K, Nie\u00dfl C, Haffner D et al (2022) Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis. Mol Genet Metab 136:282\u2013288. https:\/\/doi.org\/10.1016\/j.ymgme.2022.06.009","journal-title":"Mol Genet Metab"},{"key":"7518_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jimd.12562","volume":"46","author":"K Veys","year":"2023","unstructured":"Veys K, Zadora W, Hohenfellner K et al (2023) Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: a multicenter sibling cohort study. J Inherit Metab Dis 46:43\u201354. https:\/\/doi.org\/10.1002\/jimd.12562","journal-title":"J Inherit Metab Dis"},{"key":"7518_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/jimd.12473","volume":"45","author":"R Kluck","year":"2022","unstructured":"Kluck R, M\u00fcller S, Jagodzinski C et al (2022) Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities. J Inherit Metab Dis 45:192\u2013202. https:\/\/doi.org\/10.1002\/jimd.12473","journal-title":"J Inherit Metab Dis"},{"key":"7518_CR10","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00467-024-06421-6","volume":"39","author":"M Br\u00fcgelmann","year":"2024","unstructured":"Br\u00fcgelmann M, M\u00fcller S, Bohlen AV et al (2024) Morphological changes and their associations with clinical parameters in children with nephropathic cystinosis and chronic kidney disease prior to kidney replacement therapy over 25 years. Pediatr Nephrol 39:3067\u20133077. https:\/\/doi.org\/10.1007\/s00467-024-06421-6","journal-title":"Pediatr Nephrol"},{"key":"7518_CR11","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1210\/clinem\/dgae502","volume":"110","author":"J Lahring","year":"2025","unstructured":"Lahring J, Leifheit-Nestler M, Ewert A et al (2025) Cystinosis-associated metabolic bone disease across ages and CKD stages 1 to 5D\/T. J Clin Endocrinol Metab 110:e218\u2013e230. https:\/\/doi.org\/10.1210\/clinem\/dgae502","journal-title":"J Clin Endocrinol Metab"},{"key":"7518_CR12","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1007\/s00467-023-06058-x","volume":"38","author":"S M\u00fcller","year":"2023","unstructured":"M\u00fcller S, Kluck R, Jagodzinski C et al (2023) Chest configuration in children and adolescents with infantile nephropathic cystinosis compared with other chronic kidney disease entities and its clinical determinants. Pediatr Nephrol 38:3989\u20133999. https:\/\/doi.org\/10.1007\/s00467-023-06058-x","journal-title":"Pediatr Nephrol"},{"key":"7518_CR13","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa267","volume":"105","author":"A Ewert","year":"2020","unstructured":"Ewert A, Leifheit-Nestler M, Hohenfellner K et al (2020) Bone and mineral metabolism in children with nephropathic cystinosis compared with other CKD entities. J Clin Endocrinol Metab 105:dgaa267. https:\/\/doi.org\/10.1210\/clinem\/dgaa267","journal-title":"J Clin Endocrinol Metab"},{"key":"7518_CR14","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s00467-018-3902-x","volume":"33","author":"A Bertholet-Thomas","year":"2018","unstructured":"Bertholet-Thomas A, Claramunt-Taberner D, Gaillard S et al (2018) Teenagers and young adults with nephropathic cystinosis display significant bone disease and cortical impairment. Pediatr Nephrol 33:1165\u20131172. https:\/\/doi.org\/10.1007\/s00467-018-3902-x","journal-title":"Pediatr Nephrol"},{"key":"7518_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/bonekey.2016.55","volume":"5","author":"J Bacchetta","year":"2016","unstructured":"Bacchetta J, Greco M, Bertholet-Thomas A et al (2016) Skeletal implications and management of cystinosis: three case reports and literature review. Bonekey Rep 5:828. https:\/\/doi.org\/10.1038\/bonekey.2016.55","journal-title":"Bonekey Rep"},{"key":"7518_CR16","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/jbmr.3522","volume":"33","author":"P Florenzano","year":"2018","unstructured":"Florenzano P, Ferreira C, Nesterova G et al (2018) Skeletal consequences of nephropathic cystinosis. J Bone Miner Res 33:1870\u20131880. https:\/\/doi.org\/10.1002\/jbmr.3522","journal-title":"J Bone Miner Res"},{"key":"7518_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1093\/jbmr\/zjae092","volume":"39","author":"S Bechtold-Dalla Pozza","year":"2024","unstructured":"Bechtold-Dalla Pozza S, Lemster S, Herzig N et al (2024) Cortical impairment and reduced muscle mass in children and young adults with nephropathic cystinosis. J Bone Miner Res 39:1094\u20131102. https:\/\/doi.org\/10.1093\/jbmr\/zjae092","journal-title":"J Bone Miner Res"},{"key":"7518_CR18","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.jpeds.2016.12.049","volume":"183S","author":"E Levtchenko","year":"2017","unstructured":"Levtchenko E (2017) Endocrine complications of cystinosis. J Pediatr 183S:S5\u2013S8. https:\/\/doi.org\/10.1016\/j.jpeds.2016.12.049","journal-title":"J Pediatr"},{"key":"7518_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/humrep\/deab030","volume":"36","author":"J Rohayem","year":"2021","unstructured":"Rohayem J, Haffner D, Cremers JF et al (2021) Testicular function in males with infantile nephropathic cystinosis. Hum Reprod 36:1191\u20131204. https:\/\/doi.org\/10.1093\/humrep\/deab030","journal-title":"Hum Reprod"},{"key":"7518_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41581-019-0161-4","volume":"15","author":"J Drube","year":"2019","unstructured":"Drube J, Wan M, Bonthuis M et al (2019) Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 15:577\u2013589. https:\/\/doi.org\/10.1038\/s41581-019-0161-4","journal-title":"Nat Rev Nephrol"},{"key":"7518_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ekir.2020.11.017","volume":"6","author":"H Iyob-Tessema","year":"2021","unstructured":"Iyob-Tessema H, Wang C, Kennedy S et al (2021) Grip strength in adults and children with cystinosis. Kidney Int Rep 6:389\u2013395. https:\/\/doi.org\/10.1016\/j.ekir.2020.11.017","journal-title":"Kidney Int Rep"},{"key":"7518_CR22","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000001066","author":"CR Sheldon","year":"2025","unstructured":"Sheldon CR, Grimm PC, Long J et al (2025) Cystinosis is associated with deficits in muscle mass, strength and hip bone density in children and young adults. Kidney360. https:\/\/doi.org\/10.34067\/KID.0000001066","journal-title":"Kidney360"},{"key":"7518_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010170","volume":"11","author":"D Haffner","year":"2022","unstructured":"Haffner D, Leifheit-Nestler M, Alioli C et al (2022) Muscle and bone impairment in infantile nephropathic cystinosis: new concepts. Cells 11:170. https:\/\/doi.org\/10.3390\/cells11010170","journal-title":"Cells"},{"key":"7518_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.70116","volume":"16","author":"L Medaer","year":"2025","unstructured":"Medaer L, Mora R, Zhou Z et al (2025) An isogenic human myoblast cell model for cystinosis myopathy reveals alteration of key myogenic regulatory proteins. J Cachexia Sarcopenia Muscle 16:e70116. https:\/\/doi.org\/10.1002\/jcsm.70116","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7518_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041178","volume":"21","author":"G Battafarano","year":"2020","unstructured":"Battafarano G, Rossi M, Marampon F et al (2020) Bone control of muscle function. Int J Mol Sci 21:1178. https:\/\/doi.org\/10.3390\/ijms21041178","journal-title":"Int J Mol Sci"},{"key":"7518_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2026.103800","volume":"11","author":"A Tschirner","year":"2026","unstructured":"Tschirner A, Weber H, Schermuly K et al (2026) Markers of mineral metabolism in children with CKD stages 2 to 5D. Kidney Int Rep 11:103800. https:\/\/doi.org\/10.1016\/j.ekir.2026.103800","journal-title":"Kidney Int Rep"},{"key":"7518_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00223-020-00787-z","volume":"108","author":"F Santos","year":"2021","unstructured":"Santos F, D\u00edaz-Anad\u00f3n L, Ord\u00f3\u00f1ez FA et al (2021) Bone disease in CKD in children. Calcif Tissue Int 108:423\u2013438. https:\/\/doi.org\/10.1007\/s00223-020-00787-z","journal-title":"Calcif Tissue Int"},{"key":"7518_CR28","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00467-024-06400-x","volume":"39","author":"R Shankar","year":"2024","unstructured":"Shankar R, Saha A, Dhull RS et al (2024) Activin A: a marker of mineral bone disorder in children with chronic kidney disease? Pediatr Nephrol 39:2773\u20132777. https:\/\/doi.org\/10.1007\/s00467-024-06400-x","journal-title":"Pediatr Nephrol"},{"key":"7518_CR29","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00467-019-04421-5","volume":"36","author":"D Haffner","year":"2021","unstructured":"Haffner D, Leifheit-Nestler M (2021) CKD-MBD post kidney transplantation. Pediatr Nephrol 36:41\u201350. https:\/\/doi.org\/10.1007\/s00467-019-04421-5","journal-title":"Pediatr Nephrol"},{"key":"7518_CR30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.ajpath.2019.01.015","volume":"189","author":"G Battafarano","year":"2019","unstructured":"Battafarano G, Rossi M, Rega LR et al (2019) Intrinsic bone defects in cystinotic mice. Am J Pathol 189:1053\u20131064. https:\/\/doi.org\/10.1016\/j.ajpath.2019.01.015","journal-title":"Am J Pathol"},{"key":"7518_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0494-0","volume":"13","author":"A Conforti","year":"2015","unstructured":"Conforti A, Taranta A, Biagini S et al (2015) Cysteamine treatment restores the in vitro ability to differentiate along the osteoblastic lineage of mesenchymal stromal cells isolated from bone marrow of a cystinotic patient. J Transl Med 13:143. https:\/\/doi.org\/10.1186\/s12967-015-0494-0","journal-title":"J Transl Med"},{"key":"7518_CR32","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ndt\/gfx362","volume":"33","author":"D Claramunt-Taberner","year":"2018","unstructured":"Claramunt-Taberner D, Flammier S, Gaillard S et al (2018) Bone disease in nephropathic cystinosis is related to cystinosin-induced osteoclastic dysfunction. Nephrol Dial Transplant 33:1525\u20131532. https:\/\/doi.org\/10.1093\/ndt\/gfx362","journal-title":"Nephrol Dial Transplant"},{"key":"7518_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1681\/ASN.2013060653","volume":"25","author":"G Prencipe","year":"2014","unstructured":"Prencipe G, Caiello I, Cherqui S et al (2014) Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis. J Am Soc Nephrol 25:1163\u20131169. https:\/\/doi.org\/10.1681\/ASN.2013060653","journal-title":"J Am Soc Nephrol"},{"key":"7518_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00431-024-05851-6","volume":"184","author":"C Alioli","year":"2024","unstructured":"Alioli C, Greco M, M\u00e9aux M et al (2024) Cystinosis metabolic bone disease: inflammatory profile in human peripheral blood mononuclear cells and derived osteoclasts. Eur J Pediatr 184:9. https:\/\/doi.org\/10.1007\/s00431-024-05851-6","journal-title":"Eur J Pediatr"},{"key":"7518_CR35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1172\/JCI111806","volume":"75","author":"I Bernardini","year":"1985","unstructured":"Bernardini I, Rizzo WB, Dalakas M et al (1985) Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest 75:1124\u20131130. https:\/\/doi.org\/10.1172\/JCI111806","journal-title":"J Clin Invest"},{"key":"7518_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1172\/JCI113353","volume":"81","author":"WA Gahl","year":"1988","unstructured":"Gahl WA, Bernardini I, Dalakas M et al (1988) Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome. J Clin Invest 81:549\u2013560. https:\/\/doi.org\/10.1172\/JCI113353","journal-title":"J Clin Invest"},{"key":"7518_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1203\/00006450-199308000-00001","volume":"34","author":"WA Gahl","year":"1993","unstructured":"Gahl WA, Bernardini IM, Dalakas MC et al (1993) Muscle carnitine repletion by long-term carnitine supplementation in nephropathic cystinosis. Pediatr Res 34:115\u2013119. https:\/\/doi.org\/10.1203\/00006450-199308000-00001","journal-title":"Pediatr Res"},{"key":"7518_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092498","volume":"10","author":"T Quinaux","year":"2021","unstructured":"Quinaux T, Bertholet-Thomas A, Servais A et al (2021) Response to cysteamine in osteoclasts obtained from patients with nephropathic cystinosis: a genotype\/phenotype correlation. Cells 10:2498. https:\/\/doi.org\/10.3390\/cells10092498","journal-title":"Cells"},{"key":"7518_CR39","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1007\/s00467-021-04936-w","volume":"36","author":"V Karava","year":"2021","unstructured":"Karava V, Dotis J, Christoforidis A et al (2021) Muscle-bone axis in children with chronic kidney disease: current knowledge and future perspectives. Pediatr Nephrol 36:3813\u20133827. https:\/\/doi.org\/10.1007\/s00467-021-04936-w","journal-title":"Pediatr Nephrol"},{"key":"7518_CR40","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.nmd.2017.05.010","volume":"27","author":"M Cabrera-Serrano","year":"2017","unstructured":"Cabrera-Serrano M, Junckerstorff RC, Alisheri A et al (2017) Cystinosis distal myopathy, novel clinical, pathological and genetic features. Neuromuscul Disord 27:873\u2013878. https:\/\/doi.org\/10.1016\/j.nmd.2017.05.010","journal-title":"Neuromuscul Disord"},{"key":"7518_CR41","first-page":"42","volume":"146","author":"IC Gauer","year":"2004","unstructured":"Gauer IC, Grabenhorst U, Merz H (2004) Cystinosis: deposition of cystine crystals in the bone marrow of a 27-year-old man. MMW Fortschr Med 146:42","journal-title":"MMW Fortschr Med"},{"key":"7518_CR42","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa2506431","volume":"394","author":"BA Barshop","year":"2026","unstructured":"Barshop BA, Ball ED, Benador N et al (2026) Hematopoietic stem-cell gene therapy for cystinosis. N Engl J Med 394:753\u2013762. https:\/\/doi.org\/10.1056\/NEJMoa2506431","journal-title":"N Engl J Med"},{"issue":"3273","key":"7518_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10123273","volume":"10","author":"S Cherqui","year":"2021","unstructured":"Cherqui S (2021) Hematopoietic stem cell gene therapy for cystinosis: from bench-to-bedside. Cells 10(3273):1. https:\/\/doi.org\/10.3390\/cells10123273","journal-title":"Cells"},{"key":"7518_CR44","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1681\/ASN.0000000000000439","volume":"35","author":"F Bellomo","year":"2024","unstructured":"Bellomo F, Pugliese S, Cairoli S et al (2024) Ketogenic diet and progression of kidney disease in animal models of nephropathic cystinosis. J Am Soc Nephrol 35:1493\u20131506. https:\/\/doi.org\/10.1681\/ASN.0000000000000439","journal-title":"J Am Soc Nephrol"},{"key":"7518_CR45","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/ndt\/gfaf051","volume":"40","author":"P Romagnani","year":"2025","unstructured":"Romagnani P (2025) SGLT2 inhibitors in CKD: are they really effective in all patients? Nephrol Dial Transplant 40:1838\u20131842. https:\/\/doi.org\/10.1093\/ndt\/gfaf051","journal-title":"Nephrol Dial Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07518-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07518-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:30:13Z","timestamp":1788557413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07518-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":45,"alternative-id":["7518"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07518-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. received research grants from Chiesi, Cystinosis Research Foundation and Kyowa Kirin. D.H. received speaker and\/or consultancy fees from Advicenne, Biologix, Chiesi, Kyowa Kirin, Novo Nordisk, Medison Pharma, Recordati Rare Diseases, Sandoz, and Ultragenyx. All other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}